 | Up a level |
Friese-Hamim, Manja; Bladt, Friedhelm; Locatelli, Giuseppe; Stammberger, Uz; Blaukat, Andree (2017). The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models. American journal of cancer research, 7(4), pp. 962-972. e-Century Publishing Corporation
Francica, Paola; Nisa Hernandez, Lluis; Aebersold, Daniel; Langer, Rupert; Bladt, Friedhelm; Blaukat, Andree; Keogh-Stroka, Deborah M.; Martínez, María Rodríguez; Zimmer, Yitzhak; Medova, Michaela (2016). Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer. Clinical cancer research, 22(21), pp. 5322-5336. American Association for Cancer Research 10.1158/1078-0432.CCR-15-2987
Leiser, Dominic; Medova, Michaela; Mikami, Kei; Nisa Hernandez, Lluis; Keogh-Stroka, Deborah M.; Blaukat, Andree; Bladt, Friedhelm; Aebersold, Daniel; Zimmer, Yitzhak (2015). KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Molecular oncology, 9(7), pp. 1434-1446. Elsevier 10.1016/j.molonc.2015.04.001
Medová, Michaela; Pochon, Benoît; Streit, Bruno; Blank-Liss, Wieslawa; Francica, Paola; Stroka, Deborah; Keogh, Adrian; Aebersold, Daniel M.; Blaukat, Andree; Bladt, Friedhelm; Zimmer, Yitzhak (2013). The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants. Molecular cancer therapeutics, 12(11), pp. 2415-2424. American Association for Cancer Research AACR 10.1158/1535-7163.MCT-13-0151
Humbert, Magali; Medova, Michaela; Aebersold, Daniel; Blaukat, Andree; Bladt, Friedhelm; Fey, Martin; Zimmer, Yitzhak; Tschan, Mario P. (2013). Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochemical and biophysical research communications, 431(2), pp. 264-269. Academic Press 10.1016/j.bbrc.2012.12.120
